Cambridge, MA-based Mersana Therapeutics (MRSN) is set for its IPO that is expected to raise $75M.

The clinical-stage biopharmaceutical firm develops antibody-drug conjugates to treat cancer. Its lead product candidate is XMT-1522, a HER2-targeted ADC currently in Phase 1 development primarily in breast cancer patients. Interim safety data should be available by year-end. If all goes well, XMT-1522 will be investigated in additional types of breast cancer, non-small cell lung cancer and gastric cancer. The company expects to enter the clinic in early 2018.

READ FULL ARTICLE HERE